A device can be cleared by the FDA, stocked by a manufacturer, and recommended by a physician, and Medicare can still decline to pay for it. That is not an error in the system. It is how the system is built.
The FDA decides whether a device is safe and effective enough to be sold. The Centers for Medicare and Medicaid Services decides, separately, whether Medicare will pay for it: two agencies, two statutory standards, two timelines. Under the current process, the gap between market authorization and national Medicare coverage runs roughly a year or more, according to CMS's own description.
In April, the two agencies announced a pathway meant to shorten that to about two months for a narrow category of devices. It is worth noting that this is not yet in effect.
Why the Two Decisions Are Not the Same
The FDA asks whether a device is safe and effective for its intended use. Medicare asks whether an item is reasonable and necessary for a beneficiary, which is a different question with a different evidence base.
The specific friction is that FDA authorization often rests on studies conducted in younger, healthier populations than the Medicare population. A device shown to work in trial participants in their fifties may lack evidence in patients in their eighties with several chronic conditions. CMS is entitled to ask for that evidence, and generating it takes time.
Coverage can happen three ways. Local Medicare Administrative Contractors can decide coverage regionally, which produces the situation where the same device is covered in one state and not another. CMS can issue a national coverage determination applying everywhere, a formal process with public comment that historically takes many months. Or, absent either, individual claims get adjudicated case by case.
A national coverage determination is the decision most patients are unknowingly waiting on. It is also why "my doctor says I need it and Medicare won't pay" is a coherent sentence rather than a contradiction.
What the Proposed Pathway Would Change
On April 23, CMS and the FDA jointly announced the Regulatory Alignment for Predictable and Immediate Device coverage pathway, known as RAPID.
The mechanism is straightforward. CMS would join the FDA's early conversations with device developers, so that evidence generated for FDA review can also support the coverage decision. When an eligible device receives market authorization, CMS would issue a proposed national coverage determination the same day, triggering a 30-day comment period. National coverage could follow as soon as two months after authorization.
"The American people deserve timely access to meaningful treatments without red tape," FDA Commissioner Marty Makary said in the announcement. CMS Administrator Mehmet Oz described the pathway as "cutting red tape for innovators, and helping beneficiaries access new, life-changing health technology faster."
The eligibility criteria are narrow, and this is the part most coverage omits. The pathway applies to FDA-designated Breakthrough Devices addressing unmet needs among Medicare beneficiaries: certain Class II devices participating in the FDA's Total Product Life Cycle Advisory Program, and Class III devices regardless of participation. Devices must also be the subject of an investigational device exemption study that enrolls Medicare beneficiaries and measures clinical outcomes agreed on by both agencies.
That is a small slice of the device market. Most products a Medicare patient encounters would not qualify.
Two further caveats matter. RAPID does not create automatic coverage upon FDA authorization; it accelerates a review that still has to happen and can still end in a restriction or a denial. CMS has also paused its existing Transitional Coverage for Emerging Technologies pathway for new candidates while it implements RAPID, removing one option while the replacement is pending.
As of this publication, the proposed procedural notice had not been published in the Federal Register. A 60-day public comment period follows publication, and the pathway takes effect only when a final notice appears. More than three months after the announcement, nothing has changed operationally for any patient.
What a Patient Can Do While Waiting
None of the above helps someone whose physician has recommended a device that Medicare will not currently pay for. Several things do.
Ask precisely why coverage was denied. There is a difference between no national coverage determination existing, a determination existing that excludes your situation, a local contractor decision, and a paperwork problem such as a missing prior authorization or documentation of medical necessity. The last category is the most common and the easiest to fix.
Request the denial in writing and use the appeals process. Medicare has five levels of appeal, and denials are overturned at meaningful rates, particularly when a physician supplies documentation of medical necessity that was missing from the initial claim. Deadlines are strict, so note the date on any denial notice.
Ask your physician's office whether anyone there handles appeals or prior authorization. Many practices have staff who do this routinely and know what specific language a contractor wants.
Ask whether a covered alternative exists that would accomplish something similar. Sometimes an older device with established coverage is a reasonable option while a newer one works through review.
Ask the manufacturer about patient assistance. Device makers awaiting coverage decisions sometimes run assistance programs or clinical trials that provide access.
If you are in a Medicare Advantage plan, the rules are the plan's rather than traditional Medicare's, and the appeal process differs. Ask the plan directly for its coverage criteria in writing.
Free help exists. Every state has a State Health Insurance Assistance Program offering no-cost counseling on Medicare coverage and appeals, and the 1-800-MEDICARE line can direct you to it.
FDA authorization and Medicare coverage remain separate decisions, and the pathway meant to narrow the gap has been announced but is not yet operational. The people most affected are Medicare beneficiaries whose physicians have recommended newly authorized devices. The most reasonable action is to establish the exact reason for a denial and appeal in writing. The central uncertainty is when the proposed notice publishes, which starts a 60-day clock before anything takes effect.
Frequently Asked Questions
Why doesn't Medicare cover everything the FDA approves? Because they answer different questions. The FDA asks whether a device is safe and effective; Medicare asks whether it is reasonable and necessary for beneficiaries, often requiring evidence in older patients that FDA trials did not generate.
What is a national coverage determination? A CMS decision on whether Medicare covers an item nationwide. Without one, coverage may be decided regionally by Medicare Administrative Contractors or claim by claim.
What is the RAPID pathway? A pathway announced by CMS and the FDA in April 2026 that would let CMS propose national coverage the same day an eligible breakthrough device is authorized, potentially enabling coverage in about two months.
Is RAPID in effect now? No. The proposed procedural notice has not been published in the Federal Register. A 60-day comment period follows publication, and the pathway takes effect only upon a final notice.
Which devices would qualify? Only FDA-designated Breakthrough Devices addressing unmet needs in Medicare beneficiaries, meeting specific class and program criteria, and studied under an investigational device exemption enrolling Medicare beneficiaries.
What should I do if Medicare denies a device my doctor recommended? Get the denial in writing, establish the specific reason, and appeal. Medicare has five appeal levels with strict deadlines, and missing documentation of medical necessity is a common and fixable cause.
Where can I get free help with a Medicare denial? Every state has a State Health Insurance Assistance Program providing free Medicare counseling. Calling 1-800-MEDICARE can connect you to your state's program.
